Frédérique Vieville, Quality Director of Pherecydes Pharma, comments: “We are proud to be one of the very first French companies to obtain compassionate access authorization, associated with a Temporary Use Protocol (PUT). The close collaboration with the ANSM in recent months has enabled us to achieve this major validation for patients in therapeutic impasse. The organization is now in place to deliver our phages to all clinicians who request them. »
To receive all of Pherecydes Pharma’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.